Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.39 |
| ▸ | CTSS | P25774 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583878 | 1.00 | CTSK (0.39) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1492103 | 1.00 | CTSK (0.39) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL31374987 | 0.98 | CA1 (0.39) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1480407 | 0.98 | CA1 (0.39) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28269476 | 0.95 | CA1 (0.39) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15105800 | 0.95 | CA1 (0.39) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2377942 | 0.93 | CA1 (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15105955 | 0.93 | CA1 (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2377936 | 0.93 | CA1 (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14899075 | 0.89 | CA1 (0.37) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119306790-A | Amide derivative, composition and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4209494-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | Fujian Akeylink Biotechnology Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2417108-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-9206232-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-20130190229-A1 | VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-07-25 | — | — | US | disclosed |
| WO-2013074386-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013074386-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20130034519-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130022572-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-01-24 | — | — | US | disclosed |
| WO-2012048235-A1 | VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS | NOVARTIS AG (CH) | 2012-04-12 | — | — | WO | disclosed |
| EP-2417108-A1 | ORGANIC COMPOUNDS AND THEIR USES | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010116248-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260709-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022572-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CTSK 1630/4885CTSS 1782/4885CA1 2516/4885 |
| US-20100260709-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CTSK 1630/4885CTSS 1782/4885CA1 2516/4885 |
| US-20130034519-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CTSK 1630/4885CTSS 1782/4885CA1 2516/4885 |
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | CTSK 1314/4885CTSS 925/4885CA1 4745/4885 |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | VIP, PREP, PRAP1 | CTSK 1121/4885CTSS 2039/4885CA1 2286/4885 |
| US-20130190229-A1 | VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS | TTPA, SULT1E1, SQOR | CTSK 1225/4885CTSS 454/4885CA1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.